Sign in

Private company

NEUROPATHIX, INC.

NEUROPATHIX, INC. is an American pharmaceutical preparations company based in Doylestown.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersDoylestown, Pennsylvania1
  • Incorporated inDE2
  • Business address3805 Old Easton Road, Doylestown, Pa 189022
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-1602.7%Operating margin3
-1939.1%Net margin3
-$896.2KFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development51¢$451.8K
  • Interest49¢$434.6K

Out of $183.5K in revenue.3 The company lost money this year.

Financial statements

Revenue456783$183.5K in 2021+27% since 2015
0$50.0K$100.0K$150.0K$200.0K2015: $145.0K$145.0K20152016: $35.0K$35.0K2016−76%2017: $0$020172018: $173.9K$173.9K20182019: $126.0K$126.0K2019−28%2020: $0$020202021: $183.5K$183.5K2021
Gross profit45$1.2K in 2017−99% since 2015
0$25.0K$50.0K$75.0K$100.0K2015: $94.0K$94.0K20152016: $14.0K$14.0K2016−85%2017: $1.2K$1.2K2017−92%
Operating income456783-$2.9M in 2021
-$6.0M-$4.0M-$2.0M0$2.0M2015: $4.7K$4.7K20152016: -$32.0K-$32.0K20162017: -$1.2M-$1.2M2017+3630%2018: -$1.1M-$1.1M2018−11%2019: -$2.3M-$2.3M2019+119%2020: -$4.5M-$4.5M2020+92%2021: -$2.9M-$2.9M2021−34%
Net income456783-$3.6M in 2021
-$6.0M-$4.0M-$2.0M0$2.0M2015: $4.7K$4.7K20152016: -$32.0K-$32.0K20162017: -$1.6M-$1.6M2017+5031%2018: $931.1K$931.1K20182019: -$3.5M-$3.5M20192020: -$4.5M-$4.5M2020+31%2021: -$3.6M-$3.6M2021−22%
Fiscal year2015201620172018201920202021
Revenue$145.0K4$35.0K5$06$173.9K7$126.0K8$03$183.5K3
Cost of revenue$51.0K4$21.0K5$05
Gross profit$94.0K4$14.0K5$1.2K5
Research and development$4.0K6$224.9K7$554.7K8$1.1M3$451.8K3
Operating expenses$3.1M3
Operating income$4.7K4-$32.0K5-$1.2M6-$1.1M7-$2.3M8-$4.5M3-$2.9M3
Interest$30.8K7$146.9K8$924.2K3$434.6K3
Income before tax-$3.6M3
Income tax$05$350.0K6$812.0K7$08$03$03
Net income$4.7K4-$32.0K5-$1.6M6$931.1K7-$3.5M8-$4.5M3-$3.6M3
Earnings per share-$0.036$0.017-$0.057
Earnings per share (diluted)-$0.036$0.017-$0.057

Compare NEUROPATHIX, INC. with another company

What it owns

What NEUROPATHIX, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$69.2K3 Dec 31, 2021$59.3K3 Dec 31, 2020+16.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$15.7K3 Dec 31, 2021$21.9K3 Dec 31, 2020−28.3%

Leadership

Who has led NEUROPATHIX, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Robert Malasek2017
  2. Dean Petkanas2018–2022

Chief financial officer

  1. Robert Malasek2017
  2. Mark Corrao2018–2021
20202025
Board members and other officers (4)

Former names

  • Kannalife IncNov 2, 2018 to Nov 6, 20202
  • TYG Solutions Corp.Sep 17, 2014 to Oct 5, 20182
  • TYG Solutions Inc.Aug 21, 2014 to Aug 21, 20142

Timeline

  1. Mar 25, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares15
  2. Aug 7, 2018New chief executive Dean Petkanas becomes CEO10
  3. Jun 22, 2017New chief executive Robert Malasek becomes CEO11

Filings

12 filings to the SEC since October 2021: 1 annual reports, 2 quarterly reports, 1 major events, 3 insider forms, 1 private raises, 4 other. The latest 12:

  1. Nov 17, 2025D EDGAR
  2. Oct 20, 2023REVOKED EDGAR
  3. Aug 12, 2022NT 10-Q EDGAR
  4. Jun 13, 20224 EDGAR
  5. Jun 2, 20224 EDGAR
  6. May 23, 202210-Q EDGAR
  7. May 16, 2022NT 10-Q EDGAR
  8. Apr 15, 202210-K EDGAR
  9. Mar 31, 2022NT 10-K EDGAR
  10. Mar 25, 20228-K EDGAR
  11. Jan 7, 20224 EDGAR
  12. Nov 12, 202110-Q EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

10 open-market trades by officers, directors and large owners since October 2021: 0 buys and 10 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 9, 2022PETKANAS DEANChief Executive OfficerSale238,164$0.02$4.8KForm 4
Jun 8, 2022PETKANAS DEANChief Executive OfficerSale21,836$0.02$437Form 4
Jun 7, 2022PETKANAS DEANChief Executive OfficerSale50,000$0.02$1.0KForm 4
Jun 6, 2022PETKANAS DEANChief Executive OfficerSale10,000$0.03$300Form 4
May 31, 2022PETKANAS DEANChief Executive OfficerSale30,000$0.03$900Form 4
May 27, 2022PETKANAS DEANChief Executive OfficerSale50,000$0.03$1.5KForm 4
May 26, 2022PETKANAS DEANChief Executive OfficerSale100,000$0.03$3.0KForm 4
Jan 7, 2022PETKANAS DEANChief Executive OfficerSale41,000$0.05$2.0KForm 4
Jan 6, 2022PETKANAS DEANChief Executive OfficerSale120,000$0.05$6.0KForm 4
Jan 5, 2022PETKANAS DEANChief Executive OfficerSale89,000$0.05$4.5KForm 4

From Forms 4 filed with the SEC.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Nov 17, 2025Filed a private offering of equity16 Form D: $50 million offered in all Form D

SEC filer profile

How NEUROPATHIX, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNEUROPATHIX, INC.1
  • CIK0001615999
  • Employer ID (EIN)46-26453431
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address3805 Old Easton Road, Doylestown, PA 189021
  • Phone858-883-26421
  • Shares outstanding93,810,559 as of May 23, 20229
  • Public float$15.5M as of Jun 30, 20213
  • On EDGAR sinceAug 21, 20141
  • Filings164 in all: 4 (26), 8-K (20), 10-Q (18), S-1/A (18), UPLOAD (17), CORRESP (12), 3 (10), 10-K (6)1
    All 23 form types

    NT 10-Q (6), SC 13D (6), D (4), EFFECT (4), NT 10-K (3), S-1 (3), 4/A (2), 8-K/A (2), 10-Q/A (1), 3/A (1), 8-A12G (1), CT ORDER (1), POS AM (1), REVOKED (1), SC 13D/A (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2022
    Quarterly report (10-Q) May 23, 2022
    Latest 8-K (8-K) Mar 25, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16